Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Everest Medicines Ltd. ( (HK:1952) ) just unveiled an announcement.
Everest Medicines has entered into a connected lease transaction through a subsidiary with Kang Pu for approximately 11,459 square metres of space in Building 8 of Kangpu Life Science Industrial Park in Shanghai’s Qingpu District, to be used for research and development, production processing and ancillary warehousing. The three-year lease, starting 1 February 2026 with a possible two-year automatic extension, features a rent-free period until end-April 2026, monthly rent of RMB418,243.28 and management fees of RMB68,752.32 financed by the group’s internal resources, underscoring the company’s continued expansion of its operational footprint and dedicated facilities in a key life-science hub in China.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company that conducts research and development, production processing and related warehousing activities, with facilities in mainland China including Shanghai, positioning it within the life sciences and pharmaceutical industry.
Average Trading Volume: 3,691,400
Technical Sentiment Signal: Hold
Current Market Cap: HK$14.84B
See more data about 1952 stock on TipRanks’ Stock Analysis page.